CHRONIC OBSTRUCTIVE PULMONARY DISEASE
COPD is a lung condition characterized by common symptoms such as difficulty in breathing, severe cough with excess mucus, wheezing and tightness of chest. Affected individuals may have either chronic bronchitis or emphysema or a combination of both the conditions. Halo Dx offers advanced diagnostic tests designed to improve COPD diagnosis and to help personalize patient treatment.
Bronchitis: Characterized by inflammation of the bronchial tubes, excess mucus causing shortness of breath and cough. Nearly 9 million adults in the United States are affected (3.4%, total population)
Emphysema: Characterized by a condition where lung alveoli or air sacs are destroyed (inner walls are ruptured). It is estimated that 3.4 million U.S. adults are affected (~1.4% ) by emphysema.
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD)
The GOLD Criteria are used clinically to determine the severity of expiratory airflow obstruction for patients with COPD. Determining a patient's GOLD status requires a multidimensional assessment of a patient's spirometry, symptom burden, and frequency of COPD exacerbations.
DO NOT RELY ON GOLD SCORES ALONE
COPD is a highly heterogeneous condition and simple lung function tests may not be sufficient. Patients may have significantly different levels of emphysema, or be in different stages of the disease, despite having similar GOLD scores.
LUNG DENSITY ANALYSIS
Lung Density Analysis™ (Imbio) applies big data analysis to paired inspiratory / expiratory chest CT studies to provide visualization and quantification of lung regions with abnormal tissue density. LDA provides a full 3D DICOM series with density overlays for detailed interpretation and a quantitative report of density categories by lung region, enabling data-based decisions for personalized care.